No its not, that is for Menlo Therapeutics which for all intents and purposes does not exist anymore the two downgrades they got from $8 to $2 that sent the stock tanking were based on Menlo Therapeutics and the $2 was because they had $50+ million in cash.
Many are looking on websites, their trading platforms etc for info on MNLO and are not getting reality in regards to numbers in a whole host of issues. ER dates, EPS estimates PTs Analysts coverage etc. But I did post on another board for some longs info on the analyst coverage in the last 12 months and I do know that a lot will be cleared up going forward following the ER next week, just from a friend on the street.
Here is the post I made but anyone can also search Foamix and then put the name of the firm and it will bring up the analysts coverage as well as a host of other things, one should search Foamix earing per share estimate etc. When you search Menlo for anything it is like looking for a coke and finding RC Cola.
This is for real investors, not all the trade talk, that is not my concern.
"""As far as earnings date it is as skewed in the estimate of 9th by the internet sites as is the price targets and analysts covering it. For all intents and purposes the MNLO is not Menlo Therapeutics any more all that left of the former is the cash, the CEO and one other exec that got directors seats. The company merged in the way that it did as MNLO was already headquartered in the US while also being in close proximity with Leo Pharma for obvious reasons.
We can agree to disagree on when we think the earnings will be released but Thursday IMHO no a chance they are that late.
Price targets too are totally off kilter and bare no basis in reality. For instance when the stock got downgraded by Menlo Therapeutics H.C. Wainwright analyst Oscar Livant from $8 to $2 after the failed trials for the now scrapped Seroplant 5th/6th failure that left a zero pipeline left from the former company. It had zero to do with H.C. Wainwrights price target on Foamix.
H.C. Wainwrights analyst for Foamix (FOMX) on October 21st 2019 Ram Selvaraju reiterated his buy rating with a price target of $10.00-$11.00 and has not changed his position.
The companies that cover MNLO as it is now which is Foamix and their targets are as of now and all from the last 12 months.
H.C. Wainwright $10-$11
Barclays $10
Bank of America $11
Cantor Fitzgerald $15
Cowen $30
All are prior to Leo Pharma having remedied its supply issues for Finnaecea Foam estimated revenues for remainder of 2020 2.5 million + in royalty payments.
As well prior to the China/Taiwan/Macau licensing deal to sell Amzeeq with $11 million in one time payments + royalties.
I put this up for longs, many who were judging from my own investor group were lost as to why/how the PT's, ratings, EPS forecasts etc. had changed so drastically. The EPS estimates, PT's etc from what I understand will be sorted shortly and I expressed my opinion as such.
Stock never should have sold off but too many had no clue, they just saw downgrade Menlo Thera from $8 to 2 by 2 analysts, so, they much higher estimates by both firms remain at their higher PT's nothing has changed except there is a ton of confusion out there, but, all will know shortly you can bet that. Foamix had and still has a realistic average price target of $13 I don't count the $30 from Cowen personally, yet, I think it will happen I actually think Leo Pharma will buy it for that price within 12-18 months but in realistic terms until PDUFA June 2nd for FMX-103, the commercial launch 3-4 weeks after that and the second half of 2020 #'s bit to early for $30 but it will get there, Perceptive doesn't own 18%+ for kicks.
JMHO and only MHO while they are holding this bitch down anyone looking to hold invest in this stock while they have it trading for pennies needs to forget the name Menlo all together and do DD on Foamix as that is what it is."""
The info you pay for and get from the analyst/research firms is entirely different from what people are finding publicly when they search out any info on MNLO stock, apples and oranges. I know I pay for and get the reports from 3 of them. There isn't a price target for MNLO (Foamix) $10 let alone an average of $6.80 that's way out in left field.
Peace out.
